To investigate the phenomenon of PPI switching in the acid related disorders treatment in an Italian primary care setting during [2005][2006][2007][2008] (before and after PPIs' patents expired) and to estimate the costs of health care resources consumption associated with this phenomenon. METHODS: Retrospective cohort study was performed analyzing data from 127 GPs of Naples in the south of Italy. PPI users for ARD treatment within each study year were selected from source population. Switchers were defi ned patients changing from one PPI to another within each study year. Multivariate logistic regressions were used to assess the potential predictors of PPI switching and to investigate the factors infl uencing the direction of the switch. Cost was expressed as Euro 2008 per PPI user. RESULTS: The phenomenon of PPI switching rose from 13.0% in 2005 to 16.7% in 2008 with a peak of 18.8% in 2006. Calendar years, long-term treatments and GERD diagnosis were positive predictors of PPI switching. All years analyzed (versus 2005) were associated with switching to lansoprazole while the 2008 year was strongly associated with switching to omeprazole and pantoprazole. Very long-term treatment (>11 pack/years) group accounted for 66.3% of the total primary care cost. Switchers increased primary care costs by c61.1 compared with no switchers, reaching an incremental cost of c133.1 per useryear in the case with more than 1 switch. CONCLUSIONS: In Italy the launch of generic PPIs in the national market generates the increasing amount of chronic treatments and therapeutic substitution that will probably have had a negative impact on the total savings on PPIs, achievable by the introduction of generic products. Policy rules favouring generic PPIs prescribing can often infl uence physicians' decision to select the appropriate treatment for each patient.
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PGI30 ASSESSMENT OF FEASIBILITY OF THE METHODOLOGICAL APPROACH DESCRIBED IN THE MODEL FOR THE REGULATION OF REIMBURSEMENT PRICES IN GERMANY
Aidelsburger P 1 , Benkert D 1 , Neumann A 2 , Niebuhr D 3 , Wasem J 2 1 CAREM GmbH, Sauerlach, Germany; 2 University of Duisburg-Essen, Essen, Germany; 3 University of Applied Sciences Fulda, Fulda, Germany OBJECTIVES: The generic drug market within the statutory health insurance (SHI) in Germany is affected by price regulations like fi xed amounts or rebats. Legal amendments led to an increasing importance of price discounts with uncertain impact on pharmaceutical supply of the patients. To assure a justifi able price for the pharmaceutical companies and high quality a model has been developed by the Federal Association of Medicines Manufacturers e. V. (BAH) for the regulation of reimbursement prices, e.g. cost-benefi t based price corridors. Aim of the study is to test the described methods for feasibility. METHODS: The prior published methods for the development of reimbursement price corridors are applied and tested for feasibility by use of the indication Gastroesophageal Refl ux Disease (GERD). The methods intend the derivation of one or more corridors following a defi ned decision algorithm based on primary and secondary benefi t criteria. Therefore a systematic assessment of benefi ts of proton pump inhibitors (PPIs), H2-Blockers and sucralfat is the foundation of further decisions concerning the number of corridors to consider. Several methodical approaches for the defi nition of height of each corridor are tested. RESULTS: PPIs are more effective than H2-Blocker or sucralfat concerning primary benefi t endpoints. The assessment is based on secondary literature for fi nancial and time reasons that will be relevant when implementing the model in real decision problems, too. Based on the results of the benefi t assessment two corridors were implemented into the model. The height of each corridor can be derivated by use of angles as well as by other mathematical parameters like mean, quartiles etc. Both approaches show specifi c limitations. CONCLUSIONS: The feasibility of the reported concept can be shown. Several limitations, e.g. assessment of benefi ts based on secondary literature should be considered. Use of angles or mathematical parameter should be discussed with decision makers before implementation.
PGI31 EVALUATING THE POST OPERATIVE PRESCRIBING PRACTICES FOR APPENDICITIS IN PUBLIC HEALTH FACILITIES IN PAKISTAN
Malik M, Hussain A, Abassi N, Khan J Hamdard University, Islamabad, Punjab, Pakistan OBJECTIVES: To investigate the pattern of prescribing practices for postoperative appendicitis in public health facilities. METHODS: The study population consisted of the largest public hospital Federal Government Services Hospital (Polyclinic) from Punjab, Pakistan; Islamabad. a sample of 100 prescriptions of post operative appendicitis was collected from the public hospital. RESULTS: A total of 13.3% prescriptions out of 100 contain 2 drugs, 40% contains 3 drugs, 40 % contains 4 drugs & 6.7% contains 5 dugs. Only 6.7% prescriptions contain drugs prescribed by generic while 93.3% prescriptions were not prescribed by generic name. a total of 3.3% prescriptions contain no antibiotics, 76.6% prescriptions contain 1 antibiotic, while 20% prescriptions contain 2 antibiotics. On the other hand 23.3% prescription does not contain any injection, 10% prescriptions contain 2 injections, 23.3% prescriptions contain 3 injections, while 43.3% prescriptions contain 4 injections. One hundred percent of prescribers suggested that standard treatment guidelines and essential drug list should be available and updated regularly in hospital and must be strictly followed. a total of 33.3% of prescribers think the essential drug list should be properly regulated and updated should by the hospital management, 33.3% prescribers think by Ministry of Health while 33.3% prescribers thinks it is the duty of Hospital pharmacist. This difference was noted with respect to age of the prescriber (p = 0.020) in the prescribing practice of physicians in the public health facility. CONCLUSIONS: The major reasons for irrational drug use in case of post operative appendicitis were due to polypharmacy, overuse of antibiotics and injection and lack of standard treatment guidelines in the hospital. Thus the extent of irrational drug use in the public sector calls for in-depth investigation of the system factors and motivations that underlying these problems in the practice and the development of interventions that target the causative factors of inappropriate prescribing practice in Pakistan.
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PGI32 USING DATA ENVELOPMENT ANALYSIS TO ESTABLISH THE EFFECTIVENESS EVALUATION OF DRUGS
Wu ML Taichung Veterans General Hospital, Taichung City, Taiwan OBJECTIVES: The development and research in pharmaceutical industry has constantly created new listing drugs which provide more therapeutic effect and lower side-effects than former drugs, but the price become more expensive relatively. In order to balance the trade-off between medical quality and cost reduction, hospitals have to make the decision-making between the former drugs and the new listing drugs, which have similar therapeutic effectiveness. In this regard, the most primary issue in this research to solve is to establish a more objective and effi cient decision-making analysis that consider both effectiveness and cost for the drugs which have the similar therapeutic effect. METHODS: We use data envelopment analysis (DEA) to solve this problem, We screen six critical factors, daily drug expenses, drug profi ts, side-effect, consumption, patent duration and lead time. Evaluation of relative effi ciency of the option with DEA method must be built on the relative performance data of every input or output attributes of each decision-making unit. RESULTS: This study uses four kinds of proton pump inhibitors (PPI) for effectiveness evaluation (the code A, B, C, D drugs to replace its original name), fi rst according to defi nition of the factors to collect relevant data. We use the DEA method to treat these data, Drug a in the DEA method analysis results is the most effective (6.6542E-06), Drug D is the second (4.2381E-06), Drug B is the third (2.1165E-06) and Drug C is the worst (1.2786E-06). CONCLUSIONS: Through this research model, we transfer complex decision-making goals into various measurable or comparable factors that can compare the relative importance. The evaluation result may not let all decision-makers and users to adopt at all. But it is more comprehensive and objective to evaluate the effectiveness of decision-making models than that in the past.
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PIH1 EMERGENCY CONTRACEPTION FOR UNINTENDED PREGNANCY: ROLE OF ULIPRISTAL, A NOVEL PROGESTERONE RECEPTOR MODULATOR
Aggarwal A Heron Health Private Ltd, Chandigarh, India OBJECTIVES: Unintended pregnancies represent a global health problem with over 80 million annual pregnancies. These are associated with an increased risk of morbidity and a considerable impact on women's quality-of-life. Globally, 38% of all pregnancies are unintended resulting in 42 million induced abortions and 34 million unintended births. This corresponds to 43% of all child-births worldwide. a novel drug "Ulipristal" was introduced in Europe in May 2009 with effi cacy beyond 72 hours after unprotected coitus. The objective of this review was to determine the safety and effi cacy profi le of ulipristal compared to levonorgestrel. METHODS: A number of databases (PUBMED, EMBASE, POPLINE, CENTRAL and clinicaltrials.gov) were searched and the citations screened to identify randomised controlled trials (RCTs) reporting effi cacy and safety outcomes of ulipristal. Grey literature was searched to identify the cost associated with unintended pregnancies. Summary-statistics (Random-Effects: DerSimonian-Laird) were used to assess pregnancy and adverse-events outcomes. RESULTS: Seven RCTs were identifi ed and only two reported pregnancy outcomes. In a pooled analyses when compared to levonorgestrel, ulipristal showed better effi cacy results in preventing pregnancy following unprotected coitus on day 1 and day 3 (Day 1, RR = 0.435, [95%CI:0.148, 1.279] and Day 3, RR = 0.376, [95%CI:0.110, 1.283]). However, these results were non-signifi cant. Conversely, subgroup analysis showed that if administered on day 2, this trend was reversed with administration of levonorgestrel being associated with fewer pregnancies (RR = 1.309, [95%CI: 0.572, 2.996]). The frequency of adverse events like nausea, headache, fatigue and dizziness was similar with both the drugs. Unintended pregnancies were found to be associated with huge costs that amounted up to US$ 5 billion in US during
